Other languages Imunon, Inc.

Equities

IMNN

US15117N6022

Delayed Nasdaq Other stock markets 07:47:59 30/04/2024 pm IST			5-day change	1st Jan Change
1.29 ^USD	-4.78%		-3.01%	+89.71%

18/04	Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	MT
18/04	Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	18/04
Top Midday Gainers	28/03
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101	13/03
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff	13/03
Imunon, Inc. Announces Executive Changes	13/03
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024	13/03
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer	11/12
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer	14/11
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	18/23/18
Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board	06/23/06
Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board	14/23/14
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv	07/23/07
Imunon Opening New Manufacturing Facility in Alabama to Support Production of Vaccine Formulation Components	27/23/27
IMUNON, Inc. Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus	27/23/27
Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors	15/23/15
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Imunon, Inc.

Equities

IMNN

US15117N6022

Other languages

Filters